Trial Profile

A phase III study of Recombinant collagenase in Dupuytren's-contracture

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 14 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Recombinant collagen (Primary)
Indications Dupuytren's contracture
Focus Therapeutic Use

Most Recent Events

14 May 2024 New trial record
13 May 2024 According to a Connext media release, based on the results of phase 1/2 clinical trials, Connext plans to initiate global phase 3 clinical trials in 2026 and secure conditional approval in the European market. Based on the same mechanism of action, company plans to expand the indications to treat Peyronie's disease and cellulite

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com